Huntingtin Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Huntingtin (HTT) is a massive 3,144 amino acid, ~348 kDa protein encoded by the HTT gene on chromosome 4. It is one of the largest human proteins and is expressed ubiquitously throughout the body and brain. Wild-type (normal) huntingtin is essential for embryonic development and neuronal health, while mutant huntingtin (mHTT) with expanded polyglutamine (polyQ) repeats causes Huntington's disease (HD), an autosomal dominant neurodegenerative disorder.
The polyQ expansion is a hallmark of HD — normal HTT contains 6-35 CAG repeats, while disease-causing alleles have 36-180+ repeats. The length of the repeat correlates inversely with age of onset: longer repeats cause earlier disease onset.
¶ Domain Architecture
Huntingtin contains several functional domains:
| Domain |
Location |
Function |
| PolyQ tract |
N-terminus (1-60 aa) |
Polymorphic; expanded in HD; forms β-sheet structures when expanded |
| Polyproline region |
Adjacent to polyQ |
Mediates protein-protein interactions via SH3 domains |
| HEAT repeats |
Throughout (~23 repeats) |
Huntingtin, Elongation, A subunit, TOR; mediate protein-protein interactions |
| HEAT repeat A (HTTA) |
1-480 aa |
N-terminal interactions, membrane association |
| Nuclear export signal (NES) |
Enables nucleocytoplasmic shuttling |
|
| Nuclear localization signal (NLS) |
Allows nuclear import |
|
- Highly elongated: Predicted to be largely disordered, acting as a scaffold
- Alpha-fold prediction: Available from AlphaFold (Q13347)
- Oligomerization: Can form dimers and higher-order complexes
- Post-translational modifications: Phosphorylation, sumoylation, acetylation, ubiquitination
Wild-type HTT is essential for normal cellular function:
- Interacts with transcription factors including REST, p53, NCoR, and Sin3a
- Sequesters REST in cytoplasm; loss releases REST to nucleus causing target gene dysregulation
- Regulates brain-derived neurotrophic factor (BDNF) transcription
- Associates with synaptic vesicles through interaction with HAP40 (Huntingtin-associated protein 40)
- Facilitates dynein/dynactin-mediated transport
- Coordinates vesicle movement along microtubules
- Binds to actin and microtubules
- Supports neuronal process outgrowth
- Maintains dendritic spine morphology
- Essential for selective autophagy of damaged organelles
- Interacts with autophagy receptors
- Loss of function impairs autophagic flux
- Associates with mitochondria
- Supports mitochondrial dynamics (fusion/fission)
- Protects against mitochondrial dysfunction
- Knockout is embryonic lethal in mice
- Haploinsufficiency (50% reduction) increases neuronal vulnerability
- Required for early neurogenesis
- Normal: 6-35 CAG repeats (produces 6-35 glutamines = polyQ)
- Intermediate: 36-39 repeats (reduced penetrance)
- Disease-causing: ≥40 repeats (full penetrance)
- Juvenile HD: >60 repeats (often paternal transmission)
Longer repeats correlate with:
- Earlier age of onset
- Faster progression
- Predominant chorea or rigid/akinesia phenotype
¶ 1. Protein Misfolding and Aggregation
- Expanded polyQ adopts β-sheet conformation
- Forms intracellular inclusions (nuclear and cytoplasmic)
- Sequesters essential proteins into aggregates
- Impairs proteasome function
- Abnormal interactions with transcription factors
- Loss of BDNF expression (reduced trophic support)
- Dysregulation of neuronal genes
- Altered chromatin remodeling
- Impaired complex I, II/III, IV activity
- Reduced ATP production
- Increased ROS production
- Permeability transition pore opening
- Enhanced NMDA receptor activity
- Impaired glutamate transport
- Calcium dysregulation
- ER stress activation
- Mutant HTT disrupts autophagosome formation
- Impairs cargo recognition
- Accumulation of damaged organelles
- Disrupted vesicle trafficking
- Impaired BDNF transport
- Synaptic dysfunction
- Wild-type HTT haploinsufficiency contributes to neurodegeneration
- Normal HTT loss exacerbates mutant HTT toxicity
- Therapeutic strategies must preserve wild-type function
Tominersen (RG6042/IONIS-HTTRx):
- ASO targeting HTT mRNA
- Phase 1/2 showed dose-dependent reduction of mutant HTT in CSF [1]
- Phase 3 GENERATION-HD1 trial — initially failed to meet primary endpoint
- New analyses suggest benefit in younger patients with lower disease burden
Other ASOs:
- AAV-delivered miRNA constructs
- Allele-selective ASOs targeting expanded repeats
- CRISPR-Cas9: Editing the HTT gene to reduce mutant expression
- RNAi: shRNA/siRNA delivered via AAV
- ** zinc finger nucleases**: Gene editing approaches
| Target |
Approach |
Status |
| Mutant HTT aggregation |
Aggregation inhibitors |
Preclinical |
| Transcription |
REST inhibitors |
Preclinical |
| BDNF signaling |
Small molecule BDNF mimetics |
Preclinical |
| Mitochondrial function |
CoQ10, creatine |
Clinical trials failed |
| Neuroinflammation |
Minocycline |
Failed |
| Glutamate excitotoxicity |
AMPA antagonists |
Failed |
- Chorea: Tetrabenazine, valbenazine, antipsychotics
- Depression: SSRIs, SNRIs
- Cognitive: No approved treatments
- Mutant HTT (mHTT): Detectable in CSF; target for ASO trials
- Neurofilament light chain (NfL): Elevated in HD; tracks progression
- Imaging: Volumetric MRI shows striatal atrophy
- Cognitive testing: UHDRS, CAB-HD
The study of Huntingtin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:8454145 — HD gene discovery (1993)
- PMID:20474201 — Huntingtin and neuronal degeneration
- PMID:20206240 — Huntingtin as gene-regulatory protein
- PMID:11182455 — Loss of normal huntingtin function
- PMID:17546036 — Huntingtin and vesicle transport
- PMID:18802445 — Aggregates in Huntington disease
- PMID:31745712 — Tominersen Phase 1/2 results
- PMID:33257665 — GENERATION-HD1 trial results
- PMID:23598604 — Mitochondrial dysfunction in HD
- PMID:25359767 — Autophagy in HD